Serum Paraoxonase-1 Levels are Significantly Decreased in the Presence of Insulin Resistance

Abstract

Paraoxonase-1 (PON1) is an extracellular esterase contributing to the anti-atherogenic and anti-inflammatory properties of HDL and has a protective role in the progression of atherosclerosis. The aim of the present study was to compare serum paraoxonase-1 levels between obese subjects with prediabetes and normal glucose tolerance.

Methods: In this study were included 76 patients with mean age 50.7±10.7 years, divided into 2 age and BMI-matched groups – group 1 with obesity without glycemic disturbances (n=38) and group 2 with prediabetes (n=38). Oral glucose tolerance test (OGTT) with measurement of immunoreactive insulin was performed in all participants and levels of PON1 were measured using ELISA method.

Results: There was only a tendency towards higher PON1 levels in patients with prediabetes compared to controls. However, individuals with insulin resistance had significantly lower levels of PON1 compared to those without. The levels of PON1 showed a negative correlation with the blood glucose on 120th minute of OGTT, fasting IRI, HOMA index, BMI, WSR, WHR and particularly with waist circumference and positive with HDL-cholesterol.

Conclusions: The levels of PON1 are similar in patients with and wthout prediabetes, but are significantly decreased in patients with insulin resistance and correlate with anthropometric markers of visceral adiposity.

Key words

prediabetes - cardiovascular complications - paraoxonase - insulin reisistance

• References

• 1 de Vegt F, Dekker JM, Jager A et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population; The Hoorn study. JAMA 2001; 285: 2109-2113
• 2 Shaw JE, Zimmet PZ, de Courten M et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritus?. Diabetes care 1999; 22: 399-402
• 3 The DECODE Study Group . Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 2003; 26: 688-696
• 4 The DECODE study group . European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617-621
• 5 Ning F, Tuomilehto J, Pyorala K et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; 33: 2211-2216
• 6 Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55: 1310-1317
• 7 Qureshi AI, Giles WH, Croft JB. Impaired glucose tolerance and the likelihood of nonfatal stroke and myocardial infarction: the Third National Health and Nutrition Examination Survey. Stroke 1998; 29: 1329-1332
• 8 Durrington PN, Mackness B, Mackness M. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-480
• 9 Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154
• 10 Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009; 46: 83-106
• 11 Bhattacharyya T, Nicholls SJ, Topol EJ et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA: the journal of the American Medical Association. 2008. 299. 1265-1276
• 12 Gupta N, Binu KB, Singh S et al. Low serum PON1 activity: an independent risk factor for coronary artery disease in North-West Indian type 2 diabetics. Gene 2012; 498: 13-19
• 13 Mackness B, Davies GK, Turkie W et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457
• 14 Ayub A, Mackness MI, Arrol S et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335
• 15 Bounafaa A, Berrougui H, Ghalim N et al. Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population. PLoS One 2015; 10: e0133719
• 16 Ikeda Y, Inoue M, Suehiro T et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 2009; 46: 239-242
• 17 Zsíros N, Koncsos P, Lőrincz H et al. Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications. Clin Biochem 2016; [Epub ahead of print]
• 18 Ozgun E, Ozgun GS, Gokmen SS et al Effect of Lipoic Acid on Serum Paraoxonase-1 and Paraoxonase-3 Protein Levels and Activities in Diabetic Rats. Exp Clin Endocrinol Diabetes 2016; [Epub ahead of print]
• 19 Tabur S, Sezen H, Korkmaz H et al. High Prolidase Levels may be a Marker of Irreversible Extracellular Matrix Changes in Controlled Acromegaly Patients?. Exp Clin Endocrinol Diabetes 2016; 124: 82-86
• 20 Arancibia C, Galgani J, Valderas JP et al. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Rev Med Chil 2014; 142: 1106-1112
• 21 Ascaso J, Pardo S, Real JT et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-3325
• 22 Levitan EB, Song Y, Ford ES et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164: 2147-2155
• 23 Wen CP, Cheng TY, Tsai SP et al. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005; 28: 2756-2761
• 24 Ferretti G, Bacchetti T, Moroni C et al. Paraoxonase activity in highdensity lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005; 90: 1728-1733
• 25 Kopprasch S, Pietzsch J, Kuhlisch E et al. Chemiluminescence as a tool to assess hyperglycemia-induced systemic oxidative stress in different insulinresistant states. Abstracts of the 12th International Symposium on Bioluminescence and Chemiluminescence, Cambridge Luminescence 2002; 17: 94
• 26 Kopprasch S, Pietzsch J, Kuhlisch E et al. Lack of Association between Serum Paraoxonase 1 Activities and Increased Oxidized Low-Density Lipoprotein Levels in Impaired Glucose Tolerance and Newly Diagnosed Diabetes Mellitus. J Clin Endocrinol Metab 2003; 88: 1711-1716
• 27 Yamada A, Shoji T, Tahara H et al. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism 2001; 50: 805-811
• 28 Dursun P, Demirtas E, Bayrak A et al. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?. Human Reproduction 2006; 21: 104-108